EGFR-TKIs, such as erlotinib and osimertinib, can penetrate the blood–brain barrier5 and exhibit a pronounced treatment effect in patients with BMs.6,7 Currently, EGFR mutation status is regarded as a key prognostic factor of survival after the diagnosis of BMs.8 The gene discussed is EGFR; the disease is burning mouth syndrome.